Will Pharma Embrace Open Innovation?
The PharmTech website notes that recent years of low approvals of new blockbuster products have given rise to the perception that pharmaceutical drug development, in its current format, no longer works. Recent late-stage failures of clinical trials have also served to emphasize the risky nature of drug development. So what’s the alternative? Recently, GlaxoSmithKline placed its bets on open innovation as a new way forward for developing medicines.
Click here to read the full article.
